The United States and United Kingdom Agree to Duty-Free Accord on Drugs.
Britain and America have finalized a landmark bilateral deal that will keep zero duties on UK drug exports going into the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has agreed to increase expenditure on pharmaceuticals through the public health system. This pledge secures that import taxes on these vital products will stay at nothing for a timeframe of 36 months.
This deal is in response to previous warnings to significantly raise tariffs on branded drug imports, with figures discussed reaching 100%.
"This deal with the Britain bolsters the international landscape for innovative medicines and introduces long-overdue equity to transatlantic pharmaceutical trade," a release declared.
Economic Importance
Medicines are one of the UK's biggest goods shipped to the America, which is clearly the biggest destination for large UK drugmakers.
Statistics indicate that in the 12 months prior to last September, the UK sold pharmaceutical products valued at billions to the US. This amount represented a significant portion of all goods exports in that period.
"This deal safeguards employment, stimulates capital expenditure and facilitates the UK to emerge as a global hub for medical research," a minister stated.
Specific UK Commitments
The agreement involves several notable pledges from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to increase total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to stay within budget will be restricted at 15%. Last year, refunds were more than 20%.
Recent Tensions
The deal comes amid a long-running row between the pharmaceutical industry and the British authorities over medicine costs and approval rates.
These tensions were exacerbated by claims that US customers were paying several times more for the identical medicines than consumers in the other developed nations.
Recently, several large pharmaceutical investments in the UK have been halted or abandoned, while major funding commitments have been directed toward projects in the United States.
The Science Minister stated that the NHS must spend more on drugs, noting that its spending on drugs had declined as a share of its overall budget over the last ten years.